Genetic Predisposition for Chemotherapy-Induced Neuropathy in Multiple Myeloma

Abstract

INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-1127, 2010 4. Pardanani A, Gotlib JR, Jamieson C, et al: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789796, 2011 5. Santos FP, Kantarjian HM, Jain N, et al: Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis. Blood 115:1131-1136, 2010 6. Verstovsek S: Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 16:1988-1996, 2010 7. Barosi G, Bergamaschi G, Marchetti M, et al: JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110:4030-4036, 2007 8. Guglielmelli P, Barosi G, Specchia G, et al: Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114:1477-1483, 2009 9. Tefferi A, Lasho TL, Huang J, et al: Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22:756-761, 2008 10. Mesa RA: How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 113:5394-5400, 2009 11. Steensma DP, Mesa RA, Li CY, et al: Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study. Blood 99: 2252-2254, 2002 12. Jedidi A, Marty C, Oligo C, et al: Selective reduction of JAK2V617Fdependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 114:1842-1851, 2009 13. Mesa RA, Kantarjian H, Tefferi A, et al: Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT). J Clin Oncol 27:376s, 2009 (suppl; abstr 7083)